<p>马萨诸塞州沃特敦，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Kymera Therapeutics, Inc.（纳斯达克：KYMR），一家临床阶段的生物制药公司，正在推进一种新型口服小分子降解药物用于免疫疾病，今天宣布其承销的公开发行定价为 6.02 亿美元的普通股。Kymera 在此次发行中出售 7,000,000 股普通股，公开发行价格为每股 86.00 美元。此外，Kymera 已授予承销商一个 30 天的选择权，以每股公开发行价格购买最多 1,050,000 股普通股，扣除承销折扣和佣金。预计 Kymera 从此次发行中获得的总收益约为 6.02 亿美元，未扣除承销折扣和佣金及 Kymera 应支付的估计发行费用，假设承销商未行使购买额外股份的选择权。此次发行中出售的所有证券均由 Kymera 提供。此次发行预计于 2025 年 12 月 11 日完成，前提是满足惯例的交割条件。</p>
<p>Kymera 打算将此次发行的净收益用于继续推进其临床前和临床降解程序的管道，这些程序旨在解决具有重大需求和明确商业机会的大规模患者群体，以及用于营运资金和其他一般企业用途。</p>
<p>摩根士丹利、JP 摩根、Jefferies、Stifel、Guggenheim Securities 和富国证券担任此次发行的联合账簿管理人。</p>
<p>上述证券是根据于 2024 年 10 月 31 日向美国证券交易委员会（“SEC”）提交的自动生效的 S-3 表格注册声明（编号 333-282912）进行发行的。此次发行仅通过补充招股说明书和随附的招股说明书进行，这些文件构成注册声明的一部分。</p>
<p>与此次发行相关的最终补充招股说明书及其条款将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供。最终补充招股说明书及与此次发行相关的随附招股说明书的副本也可在可用时从摩根士丹利&amp;公司（Morgan Stanley &amp; Co. LLC）获取，注意：招股说明书部门，地址：纽约州纽约市 Varick 街 180 号，2 楼，邮政编码 10014，或通过电子邮件联系 prospectus@morganstanley.com；JP 摩根证券（J.P. Morgan Securities LLC），通过 Broadridge 金融解决方案，地址：纽约州 Edgewood，长岛大道 1155 号，邮政编码 11717，电子邮件联系 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；Jefferies LLC，邮寄至：注意：股权承销招股说明书部门，地址：纽约州纽约市麦迪逊大道 520 号，邮政编码 10022，电话：(877) 821-7388，或通过电子邮件联系 prospectus_department@jefferies.com；Stifel, Nicolaus &amp; Company, Incorporated，注意：招股说明书部门，地址：加利福尼亚州旧金山蒙哥马利街 1 号，3700 套房，邮政编码 94104，电话：(415) 364-2720，或通过电子邮件联系 syndprospectus@stifel.com；Guggenheim Securities, LLC，注意：股权承销部门，地址：纽约州纽约市麦迪逊大道 330 号，8 楼，邮政编码 10017，电话：(212) 518-9544，或通过电子邮件联系 GSEquityProspectusDelivery@guggenheimpartners.com；富国证券，地址：明尼阿波利斯南 7 街 90 号，5 楼，邮政编码 55402，电话：800-645-3751（选项#5），或通过电子邮件请求 WFScustomerservice@wellsfargo.com。</p>
<p>本新闻稿不构成出售要约或购买要约的招揽，也不构成在任何州或司法管辖区内出售这些证券的行为，除非在该州或司法管辖区的证券法下进行注册或资格审查之前。</p>
<p><strong>关于 Kymera Therapeutics</strong></p>
<p>Kymera 是一家临床阶段的生物技术公司，开创了靶向蛋白降解（TPD）领域，开发解决关键健康问题的药物，并有潜力显著改善患者的生活。Kymera 正在利用 TPD 来解决传统治疗无法触及的疾病靶点和通路。Kymera 已将首个降解剂推进到免疫疾病的临床阶段，专注于建立行业领先的口服小分子降解剂管道，为这些疾病的患者提供一代新型的方便、高效的治疗方案。Kymera 成立于 2016 年，近年来被评为波士顿最佳工作场所之一。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿中的声明可能包含 “前瞻性声明”，这些声明面临重大风险和不确定性。本新闻稿中包含的前瞻性声明可以通过使用诸如 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等词语，或这些术语的否定形式或其他类似表达来识别，包括但不限于关于预期发行的总收益、公开发行的完成和时间以及预期使用发行收益的声明。任何前瞻性声明均基于 Kymera 当前的预期、预测和假设，并且面临许多风险和不确定性，这些风险和不确定性可能导致实际结果与这些前瞻性声明中所列或暗示的结果存在重大和不利的差异。这些风险和不确定性包括但不限于与市场条件和满足公开发行相关的惯常成交条件的风险和不确定性。有关其他风险和不确定性的讨论，以及其他重要因素，任何因素都可能导致 Kymera 的实际结果与前瞻性声明中包含的结果不同，请参见 Kymera 截至 2024 年 12 月 31 日的年度报告（Form 10-K）中的 “风险因素” 部分，以及截至 2025 年 3 月 31 日、2025 年 6 月 30 日和 2025 年 9 月 30 日的季度报告（Form 10-Q），以及与公开发行相关的招股说明书补充。本文中包含的前瞻性声明基于截至本日期 Kymera 可获得的信息，仅在本发布日期作出。Kymera 没有义务更新此类信息，除非适用法律要求。投资者不应依赖任何前瞻性声明作为 Kymera 在本新闻稿日期之后的任何日期的观点。鉴于上述情况，投资者被敦促在对 Kymera 的任何证券做出任何结论或投资决策时，不要依赖任何前瞻性声明。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>投资者与媒体联系：</strong> <br/>Justine Koenigsberg<br/>副总裁，投资者关系<br/>investors@kymeratx.com<br/>media@kymeratx.com <br/>857-285-5300</td>
<td></td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOU00zTXpFMU1UQXlJekl5TURBNE16ST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOU00zTXpFMU1UQXlJekl5TURBNE16ST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTIxNDUzNmMtZjE5OS00ZGQ3LWI0ZmQtYjg2YzljNjNiMDdiLTEyMTIzODUtMjAyNS0xMi0xMC1lbg==/tiny/Kymera-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTIxNDUzNmMtZjE5OS00ZGQ3LWI0ZmQtYjg2YzljNjNiMDdiLTEyMTIzODUtMjAyNS0xMi0xMC1lbg==/tiny/Kymera-Therapeutics-Inc-.png"/></p>

KYMR

<p>Kymera Therapeutics 宣布其 6.02 亿美元公开发行的定价，出售 700 万股，每股 86 美元。此次发行预计将于 2025 年 12 月 11 日完成，所得款项将用于推进其降解剂项目和一般企业用途。摩根士丹利、摩根大通等正在管理此次发行。这些证券是在向美国证券交易委员会（SEC）提交的有效的货架注册声明下发行的</p>

<p>WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $602.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, assuming no exercise of the underwriters’ option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on December 11, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>马萨诸塞州沃特敦，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Kymera Therapeutics, Inc.（纳斯达克：KYMR），一家临床阶段的生物制药公司，正在推进一种新型口服小分子降解药物用于免疫疾病，今天宣布其承销的公开发行定价为 6.02 亿美元的普通股。Kymera 在此次发行中出售 7,000,000 股普通股，公开发行价格为每股 86.00 美元。此外，Kymera 已授予承销商一个 30 天的选择权，以每股公开发行价格购买最多 1,050,000 股普通股，扣除承销折扣和佣金。预计 Kymera 从此次发行中获得的总收益约为 6.02 亿美元，未扣除承销折扣和佣金及 Kymera 应支付的估计发行费用，假设承销商未行使购买额外股份的选择权。此次发行中出售的所有证券均由 Kymera 提供。此次发行预计于 2025 年 12 月 11 日完成，前提是满足惯例的交割条件。</p>
</div><p>Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that are designed to address large patient populations with significant need and clear commercial opportunity, and for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>Kymera 打算将此次发行的净收益用于继续推进其临床前和临床降解程序的管道，这些程序旨在解决具有重大需求和明确商业机会的大规模患者群体，以及用于营运资金和其他一般企业用途。</p>
</div><p>Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities and Wells Fargo Securities are acting as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>摩根士丹利、JP 摩根、Jefferies、Stifel、Guggenheim Securities 和富国证券担任此次发行的联合账簿管理人。</p>
</div><p>The securities described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-282912) that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 31, 2024. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement.</p>
<div class="lb-trans"><p>上述证券是根据于 2024 年 10 月 31 日向美国证券交易委员会（“SEC”）提交的自动生效的 S-3 表格注册声明（编号 333-282912）进行发行的。此次发行仅通过补充招股说明书和随附的招股说明书进行，这些文件构成注册声明的一部分。</p>
</div><p>A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Stifel, Nicolaus &amp; Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: at (212) 518-9544, or by emailing GSEquityProspectusDelivery@guggenheimpartners.com; and Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.</p>
<div class="lb-trans"><p>与此次发行相关的最终补充招股说明书及其条款将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供。最终补充招股说明书及与此次发行相关的随附招股说明书的副本也可在可用时从摩根士丹利&amp;公司（Morgan Stanley &amp; Co. LLC）获取，注意：招股说明书部门，地址：纽约州纽约市 Varick 街 180 号，2 楼，邮政编码 10014，或通过电子邮件联系 prospectus@morganstanley.com；JP 摩根证券（J.P. Morgan Securities LLC），通过 Broadridge 金融解决方案，地址：纽约州 Edgewood，长岛大道 1155 号，邮政编码 11717，电子邮件联系 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；Jefferies LLC，邮寄至：注意：股权承销招股说明书部门，地址：纽约州纽约市麦迪逊大道 520 号，邮政编码 10022，电话：(877) 821-7388，或通过电子邮件联系 prospectus_department@jefferies.com；Stifel, Nicolaus &amp; Company, Incorporated，注意：招股说明书部门，地址：加利福尼亚州旧金山蒙哥马利街 1 号，3700 套房，邮政编码 94104，电话：(415) 364-2720，或通过电子邮件联系 syndprospectus@stifel.com；Guggenheim Securities, LLC，注意：股权承销部门，地址：纽约州纽约市麦迪逊大道 330 号，8 楼，邮政编码 10017，电话：(212) 518-9544，或通过电子邮件联系 GSEquityProspectusDelivery@guggenheimpartners.com；富国证券，地址：明尼阿波利斯南 7 街 90 号，5 楼，邮政编码 55402，电话：800-645-3751（选项#5），或通过电子邮件请求 WFScustomerservice@wellsfargo.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的招揽，也不构成在任何州或司法管辖区内出售这些证券的行为，除非在该州或司法管辖区的证券法下进行注册或资格审查之前。</p>
</div><p><strong>About Kymera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Kymera Therapeutics</strong></p>
</div><p>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.</p>
<div class="lb-trans"><p>Kymera 是一家临床阶段的生物技术公司，开创了靶向蛋白降解（TPD）领域，开发解决关键健康问题的药物，并有潜力显著改善患者的生活。Kymera 正在利用 TPD 来解决传统治疗无法触及的疾病靶点和通路。Kymera 已将首个降解剂推进到免疫疾病的临床阶段，专注于建立行业领先的口服小分子降解剂管道，为这些疾病的患者提供一代新型的方便、高效的治疗方案。Kymera 成立于 2016 年，近年来被评为波士顿最佳工作场所之一。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the expected gross proceeds from the offering, completion and timing of the public offering and the anticipated use of proceeds from the offering. Any forward-looking statements are based on Kymera’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Kymera’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Kymera’s Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025, as well as in the prospectus supplement related to the public offering. Forward-looking statements contained in this press release are based on information available to Kymera as of the date hereof and are made only as of the date of this release. Kymera undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Kymera’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Kymera.</p>
<div class="lb-trans"><p>本新闻稿中的声明可能包含 “前瞻性声明”，这些声明面临重大风险和不确定性。本新闻稿中包含的前瞻性声明可以通过使用诸如 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等词语，或这些术语的否定形式或其他类似表达来识别，包括但不限于关于预期发行的总收益、公开发行的完成和时间以及预期使用发行收益的声明。任何前瞻性声明均基于 Kymera 当前的预期、预测和假设，并且面临许多风险和不确定性，这些风险和不确定性可能导致实际结果与这些前瞻性声明中所列或暗示的结果存在重大和不利的差异。这些风险和不确定性包括但不限于与市场条件和满足公开发行相关的惯常成交条件的风险和不确定性。有关其他风险和不确定性的讨论，以及其他重要因素，任何因素都可能导致 Kymera 的实际结果与前瞻性声明中包含的结果不同，请参见 Kymera 截至 2024 年 12 月 31 日的年度报告（Form 10-K）中的 “风险因素” 部分，以及截至 2025 年 3 月 31 日、2025 年 6 月 30 日和 2025 年 9 月 30 日的季度报告（Form 10-Q），以及与公开发行相关的招股说明书补充。本文中包含的前瞻性声明基于截至本日期 Kymera 可获得的信息，仅在本发布日期作出。Kymera 没有义务更新此类信息，除非适用法律要求。投资者不应依赖任何前瞻性声明作为 Kymera 在本新闻稿日期之后的任何日期的观点。鉴于上述情况，投资者被敦促在对 Kymera 的任何证券做出任何结论或投资决策时，不要依赖任何前瞻性声明。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Investor &amp; Media Contact:</strong> <br/>Justine Koenigsberg<br/>Vice President, Investor Relations<br/>investors@kymeratx.com<br/>media@kymeratx.com <br/>857-285-5300</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>投资者与媒体联系：</strong> <br/>Justine Koenigsberg<br/>副总裁，投资者关系<br/>investors@kymeratx.com<br/>media@kymeratx.com <br/>857-285-5300</td>
<td></td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOU00zTXpFMU1UQXlJekl5TURBNE16ST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg3NSM3MzE1MTAyIzIyMDA4MzI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTIxNDUzNmMtZjE5OS00ZGQ3LWI0ZmQtYjg2YzljNjNiMDdiLTEyMTIzODUtMjAyNS0xMi0xMC1lbg==/tiny/Kymera-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/OTIxNDUzNmMtZjE5OS00ZGQ3LWI0ZmQtYjg2YzljNjNiMDdiLTEyMTIzODUtMjAyNS0xMi0xMC1lbg==/tiny/Kymera-Therapeutics-Inc-.png"/></p>

Kymera Therapeutics 宣布其扩大规模的 6.02 亿美元公开发行的定价 | KYMR 股票新闻